As 2012 draws to a close, the two most impactful reforms China has set in motion within the healthcare space are the ongoing expansion of the country’s insurance plan and attempts to reform its hospitals.  The latter is one of the more complex and multi-faceted aspects of China’s overarching objectives as part of its 2009 [...]

In Part 1 of our analysis of McKinsey’s new report on China’s healthcare reforms and what they mean to your business, we spent a good bit of time discussing the policy framework evolving in the country to expand coverage of new drugs while changing the role prescription drugs played in a hospital’s revenue stream.  These [...]

Previously over at CNBC, in a past weekly column at Asia Times, and here at AHCB, I have written about the compulsory licensing regime China has adopted.  Given India’s March 2012 compulsory license of Bayer’s Nexavar, many have wondered when China will do something similar.  Right now what is known is only that China has [...]

Because the purpose of this particular column is to explore market entry strategies for western senior care operators along with some of the difficulties they are experiencing thus far in China, it is important to preface what follows with this:  I remain very bullish on this sector, and on the role western senior care companies [...]

In a recent CNBC column, I offered a glimpse into the promise and peril within China’s pharmaceutical space.  Without question, the market opportunity in China is enormous; however, the challenge of paying for drugs is more acute within the country than perhaps any other emerging economy (with the possible exception of India) purely because of [...]

Asia Healthcare Blog has long-written about the need to properly incentivize physicians and healthcare workers if China’s healthcare reforms are to succeed as imagined. But we haven’t touched on the perhaps equally important changes that would have to take place in the vast administrative network of cadres (I’m referring here to 干部) that has a [...]

In past analysis of the senior care industry (here, here, here, here and here as just a handful of examples) we have discussed the unique challenges related to finding, training, and retaining personnel in China.  Of all the strategic challenges the senior care industry faces as it expands inside of China, navigating the human resource [...]

Pioneers in China’s senior home healthcare industry include American companies Home Instead and Right at Home, along with homegrown PineTree.  Each offers the Chinese market a compelling value proposition:  the cost-effective delivery of senior care in the homes of elderly Chinese.  Each of these players has a similar business model, with varying degrees of care.  [...]